Pure Global AI
NCT06416787Not yet recruiting

Safety and Tolerability of IBI355 in Healthy Volunteers

A Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of IBI355 in Healthy Voluteers
Innovent Biologics (Suzhou) Co. Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Healthy
Drug/Device/Intervention
placebo
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
May 17, 2024
End date
Dec 30, 2025
Enrollment
32 participants
Primary outcome

Incidence of adverse events and serious adverse events

Summary

This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics
 of multiple ascending doses of IBI355 in Healthy voluteers. This study also aims to evaluate
 the anti-Drug antibody after multiple ascending doses of IBI355 in Healthy voluteers.

ICD-10 classifications
ObesitySeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personLifestyle-related conditionMalnutrition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06416787
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06416787 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.